image

image
  • Monoclonal gammopathies (MG) represent a varied group of diseases that have in common the clonal production of an immunoglobulin or fragment thereof. The monoclonal immunoglobulin (MIg) is produced by a clone of B cells, plasma cells, or lymphoplasmacytic cells and can be present in its intact form or as fragments (light, heavy, or a light and heavy chain). Systemic amyloidoses are also a rare and heterogenous group of diseases that result from the ability of certain proteins to misfold and polymerize into insoluble amyloid fibrils. These fibrils are deposited in the extracellular space of tissues and organs causing tissue damage and significant morbidity and even mortality. Amyloidosis is named by their native protein and is often classified by whether it is wild type (acquired) or the result of a germline pathogenic variant (mutant). Both MG and amyloidosis affect the kidney. In the absence of hematological malignancy, patients with a MIg in the serum and/or urine in combination with kidney involvement, are considered to have a “monoclonal gammopathy of renal significance” (MGRS). This categorization addresses a therapeutic gap as patients not meeting criteria for overt multiple myeloma were traditionally not treated, (except for AL amyloidosis and monoclonal immunoglobulin deposition disease (MIDD)). Beside AL amyloidosis the most common amyloidogenic proteins that can affect the kidneys include transthyretin (ATTR), beta-2 microglobulin (Aβ2M), serum amyloid A (AA) amyloid and leukocyte cell derived chemotaxin 2 amyloidosis (ALECT2). At the end of this course participants should be able to: Define the different types of MGRS and of amyloidosis affecting the kidney and estimate their prevalence Describe the pathogenesis of MGRS and of amyloidosis-related kidney disease Discuss the diagnostic evaluation of patients with MGRS and patients with different types of amyloidosis Illustrate the current principles of management of MGRS and the different types of amyloidosis affecting the kidney and the role of kidney transplantation


image

image

image
  • While there is an on-going increase in people with various kidney diseases, there is not a corresponding increase in the number of nephrologists required for the treatment of this vulnerable group. The care of this group in large areas of the world, especially in the low-resource settings, falls to primary care physicians/family physicians. It is important that primary care physicians are aware of the baseline evidence-based approach and diagnosis of people with underlying kidney diseases, able to render the appropriate guidelines-based care and to identify the need to refer to a specialist care facility.

  • Kidney stones are a common disease that causes significant morbidity for patients.

  • This course will provide an overview of qualitative health research. It will cover the purpose and definition of qualitative research.

  • Two renal nurse members of the ISN’s Kidney Health Professionals Working Group present on the topic of PD and HD

  • For the last 30 years, ISN’s Fellowship Program has provided grants to young doctors in low-resource settings to access high-quality, hands-on training. In-person, hands-on training at the host center will now be supplemented with online courses on the ISN Academy for a truly hybrid experience. Hybrid Fellowship modules are currently available in General Nephrology, Dialysis, Transplantation, and Pediatric Nephrology. ISN Fellows will follow the module related to their Fellowship’s primary focus, and the modules will be continually updated. Through the Hybrid Fellowship Courses, ISN Fellows will have the opportunity to learn from not only their host mentor, but also the many experts from around the world who contribute to the ISN Academy.


image
  • Objectives At the end of this course, the learner will be able to: • Understand the mechanisms, definitions and epidemiology of anemia in CKD • Remember the goals for hemoglobin and iron parameters in anemia of renal disease • Have a comprehensive overview of the major trials of anemia (iron and ESAs) in renal disease • Understand the current recommendations for iron and ESA treatment • Identify the gaps in treatment and the perspectives with new therapies, including safety and efficacy data from recent trials

  • Introduction to Interventional Nephrology Fundamentals of Vascular Anatomy Fundamentals of Vascular Access: Catheter, AVF, AVG Vascular Remodeling After AVF Creation, and Pathophysiology of Vascular Stenosis Physical Examination of AV Access Monitoring and Surveillance of AV Access Tips for CVC Placement Management of Late CVC Dysfunction: Sheath Formation, Thrombosis Management of Catheter Related Blood Stream Infection Safety Rules for IN Procedures: Radiation, Sedation, Infection Prevention Physics of Ultrasonography and its Roles in AV Access Assessment Basics knowledge on Tools Used to Perform IN Procedures PD Catheter Placement Management of Non-infectious Complications of PD Kidney Biopsy: Technique, Sample Handling, and Complications

  • AKI and Sepsis (including non dialytic treatment) Renal Screening: Part 1. Estimated vs Measured GFR for Disease Progression Are MPO and PR3 Related Vasculitis Two Distinct Clinical Entities? IgAN: A Critical Review of Therapy Glomerulonephritis New Approaches to Treatment of DKD Hemodialysis Physiologic Basis and Principles of Peritoneal Dialysis CKD Screening, Prevention, & Intervention Strategies

  • What is New in Vascular Access? My Year as an IN Fellow Renal Interdisciplinary Simulation and Education Point of Care Ultrasound Peritoneal Dialysis Catheter and COVID-19 Multidisciplinary Team Working What Does an IN Service Look Like? Introduction to Interventional Nephrology in the UK

  • From the ISN i3C (International Consortium CKDu Collaborators) network

  • With the growth of POCUS in the ER, intensive care and cardiac units, a full examination is now considered standard.


image